WTX-124是白介素-2(IL-2)INDUKINE分子,用于治疗晚期实体瘤,被设计为在肿瘤中激活后,保持对受体IL-2Ra/ß/g的高亲和力。该管线预计在2022年上半年提交IND。 WTX-330是白介素-12(IL12)的INDUKINE分子,主要在外周不与正常组织的IL-12受体的相互作用,以限制全身毒性,在肿瘤中有条件激活。预计在2022年上半年...
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in developmen...
WTX-330:a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE molecule in development as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. Werewolf is concluding IND-enabling work for WTX...
the Company presented a poster entitled “Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.” ...
Tumor growth over time was measured in mice bearing syngeneic tumors treated with either mWTX-330 (a chimeric IL-12 containing INDUKINETMmolecule) or WTX-124 (a human IL-2 containing INDUKINE molecule) using various techniques, including high-plex immunofluorescence, resulting in sign...
这些分子可全身递送但仅在肿瘤微环境内激活,目的是产生有效特异的抗肿瘤反应,同时最大限度地减少毒性。公司预计在2022年上半年为WTX-124、WTX-330申请临床研究申请,预计在2023年上半年为WTX-613申请临床研究申请。 来源:招股说明书 公司管线 4.1 WTX-124:以白介素-2(IL-2)为靶向药物,用于实体瘤...
通过专有的PREDATOR平台设计条件激活分子,刺激适应性和先天免疫,解决传统促炎免疫疗法的局限性。领先的候选产品WTX-124和WTX-330能够系统性、条件性激活白细胞介素-2(IL-2)和白细胞介素-12(IL-12),有望作为单一药物与免疫检查点抑制剂联合用于多种肿瘤治疗。
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in ...
“Following the successful completion of our IPO in early May, we believe we are well-capitalized to deliver on upcoming key milestones such as filing INDs for our two lead INDUKINE™ product candidates, WTX-124 and WTX-330, and furthering our efforts towards a safer and ...